Found 4 clinical trials
Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
The results of the International Randomized Study of Interferon and STI571 (IRIS) trial indicate that in patients with chronic phase CML treated with first line imatinib, achievement of a complete or partial cytogenetic response (CCyR or PCyR) at 12 months is associated with a significantly better progression-free survival (PFS). Second …
- 10 views
- 24 Mar, 2022
- 1 location
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
1:1 ratio to receive imatinib (Gleevec) for 2 more years (Arm A) or to stop imatinib (Arm B). The study participants are required to have histologically verified GIST with a high risk of GIST
- 7 views
- 23 Mar, 2022
- 1 location
Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
The purpose of this study is to evaluate the safety and efficacy of the tyrosine kinase inhibitor, imatinib mesylate (Gleevec ) in reducing peripheral blood eosinophilia in patients with the
- 4 views
- 30 Jun, 2022
- 1 location
A Study for Tyrosine Kinase Inhibitors Discontinuation
Treatment of Chronic Myeloid Leukemia (CML) has been revolutionized by the use of tyrosine kinase inhibitors including imatinib mesylate (Gleevec, Novartis Laboratories). Two other inhibitors of
- 0 views
- 22 Jan, 2021
- 1 location